1 Xianyao Road, Xianju, Zhejiang, China 浙江省仙居县仙药路 1 号

1 Xianyao Road, Xianju, Zhejiang, China 1 Xianyao Road, Xianju, Zhejiang, China

浙江省仙居县仙药路浙江省仙居县仙药路 11 号号

Jan. 20132013 年 7 月

A specialty pharmaceutical company dedicated to researching, manufacturing and marketing drug products in women’s health, dermatology, and pain management

The largest and most complete steroids manufacturer in China

A state-designated manufacturer of reproductive health drugs in China

仙琚制药 --- 专业的甾体药物研发和制造， 是国内规模最大、品种最为齐全的甾体药物生产厂家 --- 妇科、麻醉科产品专科生产和销售厂家

--- 生殖健康药物国家定点生产企业1 Xianyao Road, Xianju, Zhejiang, China 1 Xianyao Road, Xianju, Zhejiang, China

浙江省仙居县仙药路浙江省仙居县仙药路 11 号号

Introduction 简介

IPO on Shenzhen Stock

Exchange

Jan 2010

Reformed to Xianju Pharma

Dec 2001

Foundation of the Company

Jan 1972

公司成立1972 年 1 月

改制成立浙江仙琚制药股份有限公司

2001 年 12 月

仙琚制药国内 A 股上市

2010 年 01 月

Total assets – $300 million

总资产为 18.16 亿人民币

Facts and History 现状与历史

Sales Revenue 销售业绩

$ (Million) 单位 : 美元 ( 百万 )

Sales revenue in the past several years

近几年销售收入比较表

171193

227

269

315

146

0

50

100

150

200

250

300

350

2007 2008 2009 2010 2011 2012

($)

Wide Distribution Channels 专业销售渠道

销售系统Distribution

System

2800 家医院2800 Hospitals

3500 家医院3500 Hospitals

60000 家药店60000

Pharmacies

覆盖全球 Global coverage

覆盖全国 National coverage

制剂FPP

APIs

生殖健康产品Reproductive health

care products

麻醉科产品Anesthesiology

products

OTC 产品OTC Products

国际贸易International

Trading

国内贸易Domestic Trading

Distribution Organization 销售机构

25 个办事处25 Offices

300 多城市More than 300 Cities

1300 个代理商

1300 Agents

700 多销售员More than 700 Sales

People

制剂销售系统Distribution System

for Finished Products

Market Shares for Main Products主要产品市场占有率

• Obstetrics & Gynecology products: –Progesterone Capsules, 29.9% (1st)

• Anesthesiology products: –Rocuronium Bromide Injection, 50% (1st)–Vecuronium Bromide Injection, 50% (1st)

• OTC product: –Levonorgestrel Enteric-coated Capsules, 21.5% (2nd )

• Others: –Dexamethasone Tablets, 35%–Prednisone Acetate Tablets, 42% –Triamcinolone Acetonide Acetate Injection, 65%

• 妇产科产品：益玛欣 29.9% （第一）• 麻醉科产品：罗库溴铵注射液 50% （第一）、维库溴铵 50% （第一）

• OTC 产品：左炔肠溶胶囊 21.5% （第二）

• 其他产品：地塞米松片 35% 、强的松片 42% 、 醋酸曲安奈德注射液 65%

• Main dermatology drug: Mometasone Furoate Cream, 20.7% (2nd)

• Other dermatology products include Triamcinolone Acetonide and Econazole Cream, and Fluticasone Propionate Cream

• Distribution Channel: OTC channel and hospital terminal channel

• 皮肤科主要产品：糠酸莫米松乳膏， 20.7% （第二）• 其他皮肤科产品包括曲安奈德益康唑乳膏和丙酸氟替卡松

乳膏• 销售途径： OTC 渠道和医院途径

Market Share for Dermatology drug皮肤科产品市场占有率

Production Capacity & GMP 生产情况

Tablets: 10 billion/y 片剂 : 100 亿片 / 年Small volume injection: 200 million/y 小容量针剂 : 2 亿支 / 年Capsules: 500 million/y 胶囊剂 : 5 亿颗 / 年Lyophilized powder injection: 10 million/y 冻干粉针剂 : 1 千万支 /年Cream: 10 million/y 乳膏剂 : 1 千万支 / 年Granules: 10 million packets/y 颗粒剂 : 1 千万包 / 年Inhalation: 10 million/y 吸入剂 : 1 千万瓶 / 年API: 200 ton/y 原料药 : 200 吨 / 年

Major APIs were GMP-certified by US-FDA and EDQM

All production lines of finished products were GMP-certified by China SFDA

主要 APIs 通过 FDA 、 EDQM 官方 GMP 认证 全部制剂生产线通过中国 GMP 认证

Production Capacity 产能情况

GMP Certification GMP 认证

Xianju Institute of

Pharmaceutical R&D

仙琚药物研究院

Zhejiang Xianju Pharmaceutical

Technology Co., Ltd浙江仙琚制药技术开

发有限公司

Dept. of Product

Development

产品开发部

Dept. of Application

Tech.

应用技术部

Quality Research

质量研究室

Product Research

实验部

Joint Laboratory of Resource Chem.

and Steroid Chem.

资源化学与甾体化学联合实验室

APIs Research

原料药室

Biology and Fermentation

Research生物发酵研究室

Clinical Study

Bases

各临床研究基地

Research and Development 研发系统

Center for Intellectual

Properties 专利中心

Advisory Board

顾问团

External Collaboration with Academia

外部合作研究机构

Biologics and Fermentation

Research生物发酵研究室

Formulation Research

制剂室

130 People

噻吩诺菲Thienorphine

疫苗Vaccine

临床前Preclinical

临床 I期

Phase I

临床 II期

Phase II

临床 III期

Phase III

新药申请NDA

产品Products

治疗领域Therapeutic

Area

妇科Gynecology

镇痛Analgesia

老年痴呆 Alzheimer's

Disease

创新药研究进展 Pipelines for New Drug Development

Three innovative drugs, approximately 50 generic drugs, and 31 patents

Pipelines 项目

在研项目：创新药三个，研仿制药近 50 个 . 专利 31 项

ZXH951

Introduction of the New Plant -Yangfu Plant 新厂区 - 杨府制剂厂区介绍

• Total Area: 106,700m2

– Phase I: 48,700m2

– Phase II: 58,000m2 (Under

Construction ）总面积： 106700 ㎡– I 期： 48700 ㎡– II 期： 58000 ㎡（建设中）

• Yangfu Plant was designed based on Chinese cGMP （ 2010 ） with hardware complying to EU-GMP requirements.

按中国新版 GMP 要求设计，硬件标准达到欧美 GMP 要求

Five Year Plan –Corporate Strategy五年规划 –公司战略

Corporate Strategy• Market-driven, specialty-focused

• Enhance the leadership role in existing market.

•Expand the company rapidly by launching in-house and in-licensed products.

公司战略“ 以营销为导向”、“先做强后做大”

Five Year Plan –Corporate Objectives五年规划 –公司目标

Corporate Objectives•To become one of the Top 50 pharmaceutical companies in China

•To be China’s leading pharmaceutical company specialized in Gynecology and Anesthesiology Areas

•To establish a worldwide reputation in steroid drug manufacturing and raise brand awareness

公司目标 •整体实力进入全国制药企业 50 强•妇科、麻醉科治疗领域成为中国的领先企业•甾体药物领域成为国际知名企业

International Collaboration International Collaboration of Xianju Pharmaof Xianju Pharma

Exports of Xianju’s Products– Sales of FPP (Finished Pharmaceutical Product) in non-regulated

markets including areas and countries in Latin America, Africa, Southeast Asia.

– Sales of API (Active Pharmaceutical Ingredient) in regulated markets including EU, USA, Japan, and other areas and countries

– Collaboration model: Agent or our own employee

仙琚产品的出口销售– 制剂产品的非规范市场销售： 包括拉美、非洲、东南亚等地区和国

家– 原料药的规范市场销售： 欧盟、美国、日本等地区和国家– 合作方式：以仙琚代理或雇员方式合作

Seeking source of APIs

– Such as Dantrolene, Desogestrel, Bromocriptine, and Dydrogesterone.

– Collaboration model: Direct Importation or collaboration on manufacturing

仙琚制剂开发所需的原料药– 产品举例：丹曲林、去氧孕烯、溴隐亭、地屈孕酮等 – 合作方式：进口或合作生产

Seeking Late Stage or Approved Products – Small molecule and biological drugs: Women health, Dermatology ,

Pain Management, treatment drugs for addiction and Alzheimer's vaccine

– Medical devices: Devices and consumables for Gynecology, Anesthesiology, and Cardiothoracic surgery.

– Conduct registration and/or distribute products

产品的进口注册、销售代理– 药品：妇科、麻醉科、皮肤科、镇痛药、戒毒药和老年痴呆疫苗的

进口注册及销售代理– 生物制剂：妇科、麻醉科、皮肤科及镇痛生物制剂的进口注册及销

售代理– 器械：妇科、麻醉科、心胸科医疗器械、耗材的进口注册及销售代

理

Collaborations on New Formulations and New Technologies

– In-license and/or co-development of sustained- or controlled-release formulations

– In-license and/or co-development of new products and new technologies for steroid hormone APIs

药物新剂型、新技术合作•缓控释制剂技术、长效制剂的引进、合作开发•甾体激素原料药的新产品、新技术

Seek Partners to Create Joint Ventures in China

– To build joint ventures for research and/or manufacturing

– Target collaborators: Foreign pharmaceutical, biotech companies, as well as academia that have new technologies or products

– Areas of Interest: Innovative drugs for women’s health, dermatology and pain management, new formulations and techniques for steroids.

国内成立合资公司– 在中国成立合资实验室或合资生产基地– 合作对象：国外制药企业、研发公司、有技术或产品的专家或团队– 合作项目：妇科、麻醉科新药，激素产品新剂型、新技术，生物技

术和产品

Global Talent Recruiting Plan(Thousand-Talents Scheme)

• Xianju Pharma is collaborating with the Family Planning Commission to build a biopharma R&D platform for hereditary diseases and rare diseases.

• Seeking talents and experts who will lead efforts to establish the R&D platform.

仙琚千人计划项目合作• 仙琚与国家计生委合作打造基于遗传疾病、罕见病的生物制药研

发平台• 为平台引进国千人才及国千后备人才

Global Talent Recruiting Program(Thousand-Talents Scheme)

• Xianju Pharma has started to attract top talents since 2011 • One oversea talent has been recruited and won approval

as Expert of National Thousand-Talent Scheme in 2012• The second expert has been recruited and is waiting for

final approval in 2013

仙琚千人计划项目• 仙琚从 2011 年开始为平台引进国千人才及国千后备人才• 2012 年成功引进获批准一名国千专家。• 2013 年引进一名正等待最终批准

Qualifications for Thousand-Talent Scheme ExpertsPhD degree obtained oversea, under the age of 55 in principle. To be able to

work in China for at least 6 months a year and must meet one of the following qualifications:

• Professor or equivalent at top universities and research institutes;• Professionals and management personnel holding senior positions in well-

known international companies and financial institutions; • Entrepreneurs who possess independent intellectual property rights or

master core technologies, have overseas experience in startups and are familiar with related industries and international rules;

• Other high-level innovative talents urgently needed in China.

“千人计划”引进条件

一般应在海外取得博士学位，原则上不超过 55 岁，引进后每年在国内工作一般不少于 6 个月，并符合下列条件之一：

• 在国外著名高校、科研院所担任相当于教授职务的专家学者；• 在国际知名企业和金融机构担任高级职务的专业技术人才和经营管理人才；• 拥有自主知识产权或掌握核心技术，具有海外自主创业经验，熟悉相关产业领域和国

际规则的创业人才；• 国家急需紧缺的其它高层次创新创业人才。

Cliffs of Jingxing Cliffs of Jingxing 景星岩景星岩

Landscape of Xianju 仙居风光

Thank you !